Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update

22 Jul 2019 07:00

RNS Number : 1977G
ABCAM PLC
22 July 2019
 

22 July 2019

ABCAM PLC

 

("Abcam" or "the Group")

 

Full Year Trading Update

 

Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, is issuing today the following unaudited trading update for the year ended 30 June 2019 ahead of reporting its audited results on 9 September 2019.(1)

 

Financial performance

 

Overall, the Group expects to report total revenue of £259.9 million (2017/18: £233.2 million), representing growth for the year of 11.4% on a reported basis and 9.2% on a constant currency basis.(2)

 

Catalogue revenue, representing approximately 93% of the total, grew by 11.9% in the year on a reported basis and 9.8% on a constant currency basis, with all regions and product categories growing faster than estimated underlying market growth rates. Revenue in China grew faster than market at over 20% in the year and represents over 15% of total company sales.

 

Custom Products and Licensing (CP&L) revenue, representing approximately 7% of the total, grew by 4.7% on a reported basis and 0.4% on a constant currency basis, with gains in supply and licensing revenue offset by declines in custom project revenue.

 

The Group expects gross margin to be ahead of last year and Adjusted EBITDA(3) margin to be in line with the Board's expectations.

 

2018/19 delivery against strategy

 

The end of 2018/19 marks the fifth anniversary of the Group's 'invest-to-grow' strategy set out in 2014. Over that period, the Group made signficant strategic, operational and financial improvements to sustain double-digit growth throughout the period.

 

During the last twelve months, those investments and changes resulted in further market share gains in the global research reagents market, particularly from Recombinant antibodies, Immunoassays, and China. These market results came whilst delivering on plans to build organisational scale and seed investment for future growth in adjacent business areas.

 

Overall, the business achieved each of the strategic targets set out at the start of the year: 

 

Strategic Performance Indicators 

2018/19 target 

Actual 

Recombinant antibody product revenue growth1 

>20%

22%

Immunoassay revenue growth1 

>20%

22%

Customer engagement: transactional NPS 

57-67%

59%

1 Constant exchange rate 

 

Next five-year plan to 2023/24

 

Increasing resources dedicated to advancing medical, biopharmaceutical, and research make the outlook for Abcam's addressable markets of approximately $8bn attractive for the medium- and long-term.

 

The Board is currently reviewing its plans for the next five years to 2023/24 and sees significant opportunity to further grow the organisation organically through a programme of internally funded investments. The Group will provide details of the five-year plan alongside the presentation of its full year results on 9 September. An opportunity to explore the plans further will be offered in a Capital Markets event for institutional investors and analysts on 14 November 2019 at its new global headquarters on the Cambridge Biomedical Campus, UK.

 

Alan Hirzel, CEO of Abcam said:

 

"Life science research and biopharmaceutical customers globally once again showed their trust in Abcam to help them achieve their research mission. This trust made it possible for our business to expand our market leadership and achieve our strategic goals.

 

"The prospects for Abcam remain strong and with our focus on customers, we are confident that our investments in growth are aligned to creating long-term value for all of our stakeholders."

 

The Group will report its full year results for the twelve-month period ended 30 June 2019 on 9 September 2019. A live webcast of the presentation will be available on the Investor Relations section of the Group's website. A replay of the presentation will also be made available on the Company's website following the event. Further details of the Capital Markets event will be published in due course.

 

Abcam plc

+ 44 (0) 1223 696 000

Alan Hirzel, Chief Executive Officer

Gavin Wood, Chief Financial Officer

James Staveley, VP Investor Relations

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

 

Numis - Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Duncan Monteith

 

FTI Consulting

+44 (0) 20 3727 1000

Ben Atwell / Brett Pollard / Natalie Garland-Collins

 

Notes:

This announcement contains inside information.

 

This trading update is based upon unaudited management accounts and has been prepared solely to provide additional information on trading to the shareholders of Abcam plc. It should not be relied on by any other party for other purposes.

 

(1) This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements. The Abcam group does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law.

 

(2) Except where otherwise indicated, all revenues are provided on an unaudited, constant currency basis.

 

(3) Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation and adjusting income items. Adjusted figures exclude systems and process improvement costs associated with the implementation of the ERP, dual running costs associated with the move to the Group's new headquarters and the amortisation of acquired intangibles.

 

About Abcam plc

 

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated antibodies and assays to address important targets in critical biological pathways.

 

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

 

Some two-thirds of the world's 750,000 life science researchers use Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

 

Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 140 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

 

Please visit www.abcam.com or www.abcamplc.com to find out more.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEWFUFFUSEIW
Date   Source Headline
2nd Mar 201812:43 pmRNSTotal Voting Rights
19th Feb 20188:44 amRNSBlock listing Interim Review
2nd Feb 20185:57 pmRNSHolding(s) in Company
1st Feb 201812:26 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSAbcam Signs Exclusive License Agreement with Roche
18th Jan 201812:02 pmRNSHolding(s) in Company
8th Jan 201812:00 pmRNSAbcam present at J.P. Morgan Healthcare Conference
5th Jan 20187:00 amRNSHalf Year Trading Update
3rd Jan 20189:10 amRNSTotal Voting Rights
12th Dec 201710:37 amRNSDirector/PDMR Shareholding
1st Dec 20173:07 pmRNSTotal Voting Rights
15th Nov 20177:00 amRNSResult of AGM and Directorate Change
14th Nov 20177:00 amRNSAGM Statement
6th Nov 20174:48 pmRNSDirector/PDMR Shareholding
6th Nov 20174:42 pmRNSDirector/PDMR Shareholding
6th Nov 20174:40 pmRNSDirector/PDMR Shareholding
1st Nov 20174:46 pmRNSTotal Voting Rights
30th Oct 20179:55 amRNSDirector/PDMR Shareholding
17th Oct 20173:06 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirectorate Change
3rd Oct 201711:16 amRNSTotal Voting Rights
22nd Sep 20173:32 pmRNSAnnual Financial Report
22nd Sep 20177:00 amRNSDirector/PDMR Shareholding
18th Sep 20174:36 pmRNSDirector/PDMR Shareholding
11th Sep 20177:00 amRNSPreliminary Results
1st Sep 20179:41 amRNSTotal Voting Rights
25th Aug 201711:00 amRNSHolding(s) in Company
17th Aug 201710:00 amRNSHolding(s) in Company
9th Aug 20173:18 pmRNSBlock listing Interim Review
1st Aug 20179:45 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSPre-Close Period Update
3rd Jul 20179:54 amRNSTotal Voting Rights
7th Jun 20174:23 pmRNSDirector/PDMR Shareholding
1st Jun 20172:41 pmRNSTotal Voting Rights
18th May 20173:17 pmRNSApplication for admission to trading
18th May 20177:00 amRNSFinal Performance-Based AxioMx Milestone Payment
3rd May 201711:25 amRNSDirector/PDMR Shareholding
2nd May 201710:27 amRNSTotal Voting Rights
18th Apr 20172:24 pmRNSDirector/PDMR Shareholding
10th Apr 20173:37 pmRNSDirector/PDMR Shareholding
3rd Apr 20171:53 pmRNSTotal Voting Rights
23rd Mar 20177:00 amRNSDirector/PDMR Shareholding
21st Mar 20177:00 amRNSDirector/PDMR Shareholding
6th Mar 20177:00 amRNSInterim Results
1st Mar 20174:05 pmRNSTotal Voting Rights
9th Feb 20178:52 amRNSBlock listing Interim Review
1st Feb 201712:09 pmRNSTotal Voting Rights
10th Jan 20177:00 amRNSHalf Year Trading Update
3rd Jan 20174:34 pmRNSTotal Voting Rights
15th Dec 201611:19 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.